news
Blood tests could lead to personalised cystic fibrosis treatment
A blood test could transform the way doctors treat people affected by cystic fibrosis, helping to personalise treatments to individual people...
List view / Grid view
Cystic Fibrosis
news
Test for antibiotic associated kidney damage in children with CF identified
New research highlights effective methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis...
news
Polyphor launches the development of an inhaled antibiotic murepavadin
Polyphor Ltd has announced €5m funding, in order to support and accelerate the development of an inhaled dosage form of murepavadin...
news
Multicolour MRIs could aid disease detection
Researchers have developed a method that could make magnetic resonance imaging (MRI) multicoloured - a strategy that could serve as a research tool and even aid disease diagnosis...
news
Vertex in long-term reimbursement agreement with ROI for CF medicines
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
news
Laurent Pharmaceuticals receive $3 million for Cystic Fibrosis clinical trial
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Laurent Pharmaceuticals has received a Therapeutics Development Award of $3 million from US-based Cystic Fibrosis Foundation Therapeutics...
article
Exploring the need for mutation-specific treatments in cystic fibrosis
1 July 2016 | By Caroline Richards, Editor, European Pharmaceutical Review
Here, Caroline Richards, Editor of European Pharmaceutical Review, discusses cystic fibrosis and the treatment options that are currently available or in development...
news
Verona secures funding commitments to help progress RPL554
20 June 2016 | By Victoria White, Digital Content Producer
Verona Pharma has successfully secured funding commitments to raise gross proceeds of £44.7m through a conditional placing with new and existing investors...
news
Orkambi’s cost too high for benefit offered, says NICE
17 June 2016 | By Victoria White, Digital Content Producer
NICE has said it will not be able to recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis...
news
Polyphor successfully completes Phase I study with POL6014
6 June 2016 | By Victoria White, Digital Content Producer
POL6014 is a highly selective, potent and reversible inhibitor of hNE. Increased levels of hNE is associated with cystic fibrosis...
news
SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
news
Polyphor awarded $3 million to advance POL6014 in CF
23 March 2016 | By Victoria White
Polyphor's POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess...
news
NICE says ‘no’ to cystic fibrosis drug Orkambi in draft guidance
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
article
European Pharmaceutical Review’s top 10 stories from 2015
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
news
EC grants marketing authorisation for cystic fibrosis drug Orkambi
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
